EU awards large funding to develop data-driven collaboration between European Pediatric Hospitals
11.10.2023 11:34:29 EEST | HUS | Press release
PHEMS project will advance data-driven research and innovation activities in pediatrics and the use of privacy-preserving datasets in Europe. The project’s aim is to overcome important barriers that currently hinder cross-border collaboration on health data by developing and validating a decentralized health data ecosystem. This will enable an ecosystem without central data repositories or release of sensitive personal health data from hospitals.

A consortium led by HUS Helsinki University Hospital has received significant EU funding for developing data collaboration between European Children’s Hospitals in a privacy-preserving manner. Progress in this area will help the development of new therapies for children, the assessment of pediatric care outcomes and the advancement of new technology solutions such as artificial intelligence in pediatrics. The project will start in October 2023 and go on until September 2026. It has been awarded a total funding of 7 M€ from the Horizon Europe programme and from the UK research funding agency.
“We will enable European collaboration on health data by aligning ethical and legal requirements of leading European pediatric hospitals with the needs of data users. This ensures that researchers can benefit from rich datasets and advance scientific research in pediatrics while the patient’s rights and data privacy remain protected” states Katariina Gehrmann, Director of Digital and Innovation Services at HUS New Children’s Hospital.
To achieve this, the project develops new technological solutions that facilitate authorized access to health data at multiple locations and advances federated health data analysis together with next-generation anonymization. In addition, the project develops shared rules and governance structures, which allow new partners to join and new datasets to be included in the ecosystem.
“One challenge with algorithmically anonymized and synthetized datasets is the lack of evidence on their validity and utility for real-world needs in research or healthcare management. Therefore, we shall perform studies on three clinical use cases and aim to generate evidence in different clinical areas and in the management of healthcare operations” continues Gehrmann.
The Consortium consists of six leading European pediatric hospitals from the European Children's Hospital Organization (ECHO) community and of leading-edge technical partners. The ECHO community advocates for children’s health and their access to the best quality care through the collaborative work of children’s hospitals.
The consortium hospital partners are HUS Helsinki University Hospital (Finland), Erasmus Universitair Medisch Centrum Rotterdam (Netherlands), Meyer Children's Hospital IRCCS in Florence (Italy), SJD Barcelona Children’s Hospital (Spain), Great Ormond Street Hospital for Children in London (United Kingdom), Bērnu klīniskā universitātes slimnīca (Latvia) In addition to Childrens’ Hospitals, the PHEMS consortium includes technology partners: Tietoevry Finland Oy (Finland), Aridhia Informatics Limited (UK) and VEIL.AI Oy (Finland) and two professional services partners: The Hyve B.V. (Netherlands) and GENESIS Biomed (Spain). The proposal preparation was supported by company specialized in EU-funding, namely Spinverse.
Keywords
Contacts
Katariina GehrmannDirector of Digital and Innovation ServicesNew Children’s Hospital, HUS Helsinki University Hospital
Tel:+358 40 730 7741katariina.gehrmann@hus.fiImages
About HUS
HUS Helsinki University Hospital is the biggest provider of specialized healthcare in Finland. Our high expertise is internationally recognized and accredited. As a university hospital, we are on the cutting edge of developing and evaluating our treatment methods and activities.
HUS treats almost 700,000 patients every year. Our nearly 27,000 professionals work to provide the best possible care for our patients. We are responsible for organizing specialized health care in the Uusimaa region. The treatment of many rare and difficult diseases in Finland has been centralized to HUS as well.
HUS – Leading healthcare
The HUS media service is available for the media Mon–Thu 10:00 a.m.-4:00 p.m. and Fri 10:00 a.m.–3:00 p.m., tel. 050 427 2875, or via e-mail: viestinta@hus.fi.
Alternative languages
Subscribe to releases from HUS
Subscribe to all the latest releases from HUS by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from HUS
Studie gav ny kunskap om immunförsvaret vid leukemi29.9.2026 08:26:54 EEST | Pressmeddelande
Forskare vid HUS Cancercentrum och Helsingfors universitet utredde hur immunsystemet hos patienter med akut myeloisk leukemi reagerade på experimentell immunterapi. Förändringar som hänför sig till terapiresponsen visade sig i andra immunceller än förväntat baserat på tidigare studier.
Tutkimus toi uutta tietoa leukemian immuunipuolustuksesta29.9.2026 08:26:54 EEST | Tiedote
HUSin Syöpäkeskuksen ja Helsingin yliopiston tutkijat selvittivät, miten akuuttia myelooista leukemiaa sairastavien potilaiden immuunijärjestelmä reagoi kokeelliseen immunoterapiaan. Hoitovasteeseen liittyvät muutokset näkyivät eri immuunisoluissa kuin aiempien tutkimusten perusteella olisi voitu odottaa.
Study provides new insights into the immune response in leukemia29.9.2026 08:26:54 EEST | Press release
Researchers at HUS Comprehensive Cancer Center and the University of Helsinki investigated how the immune systems of patients with acute myeloid leukemia (AML) respond to experimental immunotherapy. The study found that changes associated with treatment response were observed in different immune cell types than would have been expected based on previous research.
Genetiska undersökningar kan avslöja orsaken till plötslig oförklarlig död hos unga14.9.2026 09:18:15 EEST | Pressmeddelande
Den bakomliggande orsaken till plötslig oförklarlig död hos unga kan vara en sällsynt ärftlig sjukdom som nödvändigtvis inte kommer fram i vanliga undersökningar. Genetiska undersökningar är en viktig del särskilt i utredningen av plötsliga oväntade dödsfall hos unga. Genetiska undersökningar kan också bidra till att identifiera släktingar som omfattas av risken och förebygga eventuella allvarliga hjärthändelser.
Geenitutkimus voi paljastaa syyn nuoren selittämättömälle äkkikuolemalle14.9.2026 09:18:15 EEST | Tiedote
Nuoren selittämättömän äkkikuoleman taustalla voi olla harvinainen perinnöllinen sairaus, joka ei välttämättä tule esiin tavanomaisissa tutkimuksissa. Geenitutkimus on tärkeä osa erityisesti nuorten odottamattomien äkkikuolemien syyn selvittämisessä. Geenitutkimus voi myös auttaa tunnistamaan riskissä olevia sukulaisia ja ehkäistä mahdollisia vakavia sydäntapahtumia.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom

